European Journal of Clinical Pharmacology

, Volume 63, Issue 4, pp 321–333 | Cite as

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

  • D. FrankEmail author
  • U. Jaehde
  • U. Fuhr
Review Article



Cytochrome P450 2D6 (CYP2D6) is one of the most important enzymes catalyzing biotransformation of xenobiotics in the human liver. This enzyme’s activity shows a high degree of interindividual variability caused in part by its genetic polymorphism, the so-called debrisoquine/sparteine polymorphism. The genetic component influencing CYP2D6 activity can be determined by genotyping. However, genotyping alone is not sufficient to accurately predict an individual’s actual CYP2D6 activity, as this is also influenced by other factors. For the determination of the exact actual enzymatic activity (“phenotyping”), adequate probe drugs have to be administered prior to measurements of these compounds and/or their metabolites in body fluids.

Probe drugs

Debrisoquine, sparteine, metoprolol or dextromethorphan represent well-established probe drugs while tramadol has been recently investigated for this purpose. The enzymatic activity is reflected by various pharmacokinetic metrics such as the partial clearance of a parent compound to the respective CYP2D6-mediated metabolite or metabolic ratios. Appropriate metrics need to fulfill pre-defined validation criteria.


In this review, we have compiled a list of such criteria useful to select the best metrics to reflect CYP2D6 activity. A comprehensive Medline search for reports on CYP2D6 phenotyping trials with the above mentioned probe drugs was carried out.


Application of the validation criteria suggests that dextromethorphan and debrisoquine are the best CYP2D6 phenotyping drugs, with debrisoquine having the problem of very limited availability as a therapeutic drug. However, the assessment of the best dextromethorphan CYP2D6 phenotyping metric/procedure is still ongoing.


CYP2D6 phenotyping Debrisoquine Sparteine Metoprolol Dextromethorphan Tramadol 


  1. 1.
    Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall RR, Medve R, Liao S, Spielberg SP, Kearns GL (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42:24–29PubMedCrossRefGoogle Scholar
  2. 2.
    al-Hadidi HF, Irshaid YM, Rawashdeh NM (1994) Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 47:311–314PubMedCrossRefGoogle Scholar
  3. 3.
    Barnhart JW (1980) The urinary excretion of dextromethorphan and three metabolites in dogs and humans. Toxicol Appl Pharmacol 55:43–48PubMedCrossRefGoogle Scholar
  4. 4.
    Basci NE, Bozkurt A, Kayaalp SO, Sayal A, Isimer A (1998) Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan. Eur J Drug Metab Pharmacokinet 23:1–5PubMedCrossRefGoogle Scholar
  5. 5.
    Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol 17:153–155PubMedCrossRefGoogle Scholar
  6. 6.
    Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122PubMedCrossRefGoogle Scholar
  7. 7.
    Bertz RJ, Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–258PubMedGoogle Scholar
  8. 8.
    Bock KW, Schrenk D, Forster A, Griese EU, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209–218PubMedCrossRefGoogle Scholar
  9. 9.
    Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC (2005) Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 33:1052–1055PubMedCrossRefGoogle Scholar
  10. 10.
    Bozkurt A, Basci NE, Isimer A, Sayal A, Kayaalp SO (1996) Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Eur J Drug Metab Pharmacokinet 21:309–314PubMedCrossRefGoogle Scholar
  11. 11.
    Brosen K, Otton SV, Gram LF (1986) Sparteine oxidation polymorphism: a family study. Br J Clin Pharmacol 21:661–667PubMedGoogle Scholar
  12. 12.
    Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996) The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther 60:295–307PubMedCrossRefGoogle Scholar
  13. 13.
    Cerqueira PM, Coelho EB, Geleilete TJ, Goldman GH, Lanchote VL (2005) Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. J Clin Pharmacol 45:1422–1433PubMedCrossRefGoogle Scholar
  14. 14.
    Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5 + 1 cocktail”. Clin Pharmacol Ther 74:437–447PubMedCrossRefGoogle Scholar
  15. 15.
    Chladek J, Zimova G, Martinkova J, Tuma I (1999) Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects. Fundam Clin Pharmacol 13:508–515PubMedCrossRefGoogle Scholar
  16. 16.
    Chladek J, Zimova G, Beranek M, Martinkova J (2000) In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol 56:651–657PubMedCrossRefGoogle Scholar
  17. 17.
    Dalen P, Dahl M, Andersson K, Bertilsson L (2000) Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol 49:180–184PubMedCrossRefGoogle Scholar
  18. 18.
    Dayer P, Desmeules J, Leemann T, Striberni R (1988) Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 152:411–416PubMedCrossRefGoogle Scholar
  19. 19.
    Dayer P, Leemann T, Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther 45:34–40PubMedCrossRefGoogle Scholar
  20. 20.
    Distlerath LM, Guengerich FP (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc Natl Acad Sci USA 81:7348–7352PubMedCrossRefGoogle Scholar
  21. 21.
    Duche JC, Querol-Ferrer V, Barre J, Mesangeau M, Tillement JP (1993) Dextromethorphan O-demethylation and dextrorphan glucuronidation in a French population. Int J Clin Pharmacol Ther Toxicol 31:392–398PubMedGoogle Scholar
  22. 22.
    Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183–187PubMedCrossRefGoogle Scholar
  23. 23.
    Eichelbaum M, Bertilsson L, Sawe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31:184–186PubMedCrossRefGoogle Scholar
  24. 24.
    Eichelbaum M, Mineshita S, Ohnhaus E, Zekorn C (1986) The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 22:49–53PubMedGoogle Scholar
  25. 25.
    Evans WE, Relling MV (1991) Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Pharmacogenetics 1:143–148PubMedCrossRefGoogle Scholar
  26. 26.
    Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther (in press)Google Scholar
  27. 27.
    Funck-Brentano C, Boelle PY, Verstuyft C, Bornert C, Becquemont L, Poirier JM (2005) Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. Eur J Clin Pharmacol 61:821–829PubMedCrossRefGoogle Scholar
  28. 28.
    Fux R, Morike K, Prohmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivisto KT (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78:378–387PubMedCrossRefGoogle Scholar
  29. 29.
    Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 351:2827–2831PubMedCrossRefGoogle Scholar
  30. 30.
    Granvil CP, Krausz KW, Gelboin HV, Idle JR, Gonzalez FJ (2002) 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther 301:1025–1032PubMedCrossRefGoogle Scholar
  31. 31.
    Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8:15–26PubMedCrossRefGoogle Scholar
  32. 32.
    Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173PubMedCrossRefGoogle Scholar
  33. 33.
    Hou ZY, Pickle LW, Meyer PS, Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49:410–419PubMedCrossRefGoogle Scholar
  34. 34.
    Hou ZY, Chen CP, Yang WC, Lai MD, Buchert ET, Chung HM, Pickle LW, Woosley RL (1996) Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis. Clin Pharmacol Ther 59:411–417PubMedCrossRefGoogle Scholar
  35. 35.
    Hu OY, Tang HS, Lane HY, Chang WH, Hu TM (1998) Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 285:955–960PubMedGoogle Scholar
  36. 36.
    Jacqz E, Dulac H, Mathieu H (1988) Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 35:167–171PubMedCrossRefGoogle Scholar
  37. 37.
    Jacqz-Aigrain E, Funck-Brentano C, Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197–204PubMedCrossRefGoogle Scholar
  38. 38.
    Johnson JA, Burlew BS (1996) Metoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos 24:350–355PubMedGoogle Scholar
  39. 39.
    Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Shirey CS, Gotschall R, Gaedigk A, Bertino JS Jr (1998) Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8:403–410PubMedCrossRefGoogle Scholar
  40. 40.
    Kevorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C (1996) Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clin Pharmacol Ther 59:583–592PubMedCrossRefGoogle Scholar
  41. 41.
    Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083–1105PubMedCrossRefGoogle Scholar
  42. 42.
    Kim M, Shen DD, Eddy AC, Nelson WL, Roskos LK (1993) Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab Dispos 21:309–317PubMedGoogle Scholar
  43. 43.
    Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473PubMedCrossRefGoogle Scholar
  44. 44.
    Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S–48SPubMedGoogle Scholar
  45. 45.
    Kohler D, Hartter S, Fuchs K, Sieghart W, Hiemke C (1997) CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 7:453–461PubMedCrossRefGoogle Scholar
  46. 46.
    Kupfer A, Schmid B, Pfaff G (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421–433PubMedCrossRefGoogle Scholar
  47. 47.
    Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10:425–438PubMedCrossRefGoogle Scholar
  48. 48.
    Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K (2005) Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312–323PubMedCrossRefGoogle Scholar
  49. 49.
    Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker LE, Woods HF (1982) Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 307:1558–1560PubMedCrossRefGoogle Scholar
  50. 50.
    Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 34:732–737PubMedCrossRefGoogle Scholar
  51. 51.
    Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF (1992) Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 2:89–92PubMedCrossRefGoogle Scholar
  52. 52.
    Lu AY, Wang RW, Lin JH (2003) Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 31:345–350PubMedCrossRefGoogle Scholar
  53. 53.
    Lutz U, Volkel W, Lutz RW, Lutz WK (2004) LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation. J Chromatogr B Analyt Technol Biomed Life Sci 813:217–225PubMedGoogle Scholar
  54. 54.
    Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584–586PubMedCrossRefGoogle Scholar
  55. 55.
    Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51:117–122PubMedCrossRefGoogle Scholar
  56. 56.
    Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247:242–427PubMedGoogle Scholar
  57. 57.
    Ozdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A (2004) Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol 44:1398–1404PubMedCrossRefGoogle Scholar
  58. 58.
    Paar WD, Frankus P, Dengler J (1992) The metabolism of tramadol by human liver microsomes. Clin Investig 70:708–710PubMedCrossRefGoogle Scholar
  59. 59.
    Paar WD, Poche S, Gerloff J, Dengler HJ (1997) Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesis tramadol. Eur J Pharmacol 53:235–239CrossRefGoogle Scholar
  60. 60.
    Paar WD, Schuhler H, Fimmers R, Dengler HJ (1989) Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. Eur J Clin Pharmacol 36:555–560 cytochrome P450 2D6. J Biol Chem 278:4021–4027Google Scholar
  61. 61.
    Pedersen RS, Damkier P, Brosen K (2005) Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 77:458–467PubMedCrossRefGoogle Scholar
  62. 62.
    Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH (1996) The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 60:636–644PubMedCrossRefGoogle Scholar
  63. 63.
    Rostami-Hodjegan A, Kroemer HK, Tucker GT (1999) In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9:277–286PubMedCrossRefGoogle Scholar
  64. 64.
    Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295PubMedGoogle Scholar
  65. 65.
    Schellens JH, Soons PA, van der Wart JH, Hoevers JW, Breimer DD (1991) Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. Br J Clin Pharmacol 31:175–178PubMedGoogle Scholar
  66. 66.
    Schellens JH, van der Wart JH, Brugman M, Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther 249:638–645PubMedGoogle Scholar
  67. 67.
    Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618–624PubMedCrossRefGoogle Scholar
  68. 68.
    Sloan TP, Lancaster R, Shah RR, Idle JR, Smith RL (1983) Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol 15:443–450PubMedGoogle Scholar
  69. 69.
    Sohn DR, Kusaka M, Shin SG, Jang IJ, Chiba K, Ishizaki T (1992) Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations. Ther Drug Monit 14:184–189PubMedCrossRefGoogle Scholar
  70. 70.
    Sommers DK, Moncrieff J, Avenant J (1989) Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Hum Toxicol 8:365–368PubMedGoogle Scholar
  71. 71.
    Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394–401PubMedCrossRefGoogle Scholar
  72. 72.
    Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr (1999) Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. Clin Pharmacol Ther 66:535–541PubMedCrossRefGoogle Scholar
  73. 73.
    Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216PubMedCrossRefGoogle Scholar
  74. 74.
    Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, Lake BG (2001) Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29:1146–1155PubMedGoogle Scholar
  75. 75.
    Syvalahti EK, Lindberg R, Kallio J, De Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89–92PubMedGoogle Scholar
  76. 76.
    Takashima T, Murase S, Iwasaki K, Shimada K (2005) Evaluation of dextromethorphan metabolism using hepatocytes from CYP2D6 poor and extensive metabolizers. Drug Metab Pharmacokinet 20:177–182PubMedCrossRefGoogle Scholar
  77. 77.
    Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA, de Leij LF, Jonkman JH (2001) An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 57:143–146PubMedCrossRefGoogle Scholar
  78. 78.
    Tanaka E, Kurata N, Yasuhara H (2003) How useful is the “cocktail approach” for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 28:157–165PubMedCrossRefGoogle Scholar
  79. 79.
    Tegeder I, Lotsch J, Geisslinger G (1999) Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 37:17–40PubMedCrossRefGoogle Scholar
  80. 80.
    von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997–1004Google Scholar
  81. 81.
    Yeh GC, Tao PL, Ho HO, Lee YJ, Chen YJ, Sheu MT (2003) Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 10:552–564PubMedCrossRefGoogle Scholar
  82. 82.
    Yu A, Dong H, Lang D, Haining RL (2001) Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362–1365PubMedGoogle Scholar
  83. 83.
    Yu A, Haining RL (2001) Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos 29:1514–1520PubMedGoogle Scholar
  84. 84.
    Yu AM, Idle JR, Herraiz T, Kupfer A, Gonzalez FJ (2003) Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:307–319PubMedCrossRefGoogle Scholar
  85. 85.
    Zaigler M, Tantcheva-Poor I, Fuhr U (2000) Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. Int J Clin Pharmacol Ther 38:1–9PubMedGoogle Scholar
  86. 86.
    Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol 369:23–37CrossRefGoogle Scholar
  87. 87.
    Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 70:455–461PubMedCrossRefGoogle Scholar
  88. 88.
    Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76:536–544PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Pharmacology, Clinical PharmacologyUniversity of CologneKölnGermany
  2. 2.Department of Clinical Pharmacy, Institute of PharmacyUniversity of BonnBonnGermany

Personalised recommendations